Key Events This Week
25 May: New 52-week and all-time high reached at Rs.2,620
26 May: Strong quarterly results reported amid margin pressures
27 May: Valuation shift noted, enhancing price attractiveness
29 May: Stock rebounds with a 5.27% gain despite Sensex decline

Fredun Pharmaceuticals Ltd is Rated Hold
2026-05-28 10:10:30Fredun Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 28 May 2026, providing investors with the latest insights into its performance and outlook.
Read full news article
Fredun Pharmaceuticals Ltd: Valuation Shift Enhances Price Attractiveness Amid Robust Returns
2026-05-27 08:01:41Fredun Pharmaceuticals Ltd has undergone a notable shift in its valuation parameters, moving from an expensive to an attractive price range. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positions the micro-cap pharmaceutical company as a compelling consideration within its sector amid robust returns and improving fundamentals.
Read full news article
Fredun Pharmaceuticals Reports Strong Quarterly Gains Amid Margin Pressures
2026-05-26 08:00:15Fredun Pharmaceuticals Ltd has delivered its highest quarterly revenue and profit figures in the March 2026 quarter, signalling robust top-line growth despite emerging margin pressures and increased interest costs. The company’s financial trend has moderated from very positive to positive, reflecting a nuanced performance that investors should carefully analyse amid a recent downgrade in its Mojo Grade to Hold.
Read full news article
Broad-Based Technical Strength Lifts Fredun Pharmaceuticals Ltd to 52-Week High of Rs 2620
2026-05-25 10:48:41Surging past its previous peaks, Fredun Pharmaceuticals Ltd touched a new 52-week high of Rs 2620 on 25 May 2026, marking a remarkable 253.81% gain over the past year. This milestone comes amid a backdrop of strong technical momentum and sustained earnings growth, setting the stage for a compelling price rally within the pharmaceuticals sector.
Read full news articleFredun Pharmaceuticals Gains 6.86%: Four Key Factors Driving the Surge
2026-05-23 13:06:03
Key Events This Week
18 May: Stock opens at Rs.2,302.55, down 2.70%
21 May: New 52-week and all-time high at Rs.2,560
22 May: Hits record high of Rs.2,619.95
22 May: Week closes at Rs.2,528.85, up 6.86%

Broad-Based Technical Strength Lifts Fredun Pharmaceuticals Ltd to 52-Week High of Rs 2619.95
2026-05-22 09:47:36Surging past its previous peaks, Fredun Pharmaceuticals Ltd reached a new 52-week high of Rs 2619.95 on 22 May 2026, marking a remarkable rally that has seen the stock gain over 250% in the past year. This milestone reflects a powerful confluence of technical momentum and sustained price strength, setting the stage for further market attention.
Read full news articleAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
10-Jun-2026 | Source : BSEAudio Recording of the Q4 and year ended for the FY26 Earnings Conference Call
Announcement under Regulation 30 (LODR)-Newspaper Publication
09-Jun-2026 | Source : BSENewspaper Clipping- Information regarding 39th Annual General Meeting to be held on 30th June 2026 through video conference/other audio visual means.
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations).
08-Jun-2026 | Source : BSEIntimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)
Corporate Actions
No Upcoming Board Meetings
Fredun Pharmaceuticals Ltd has declared 7% dividend, ex-date: 23 Jun 26
No Splits history available
No Bonus history available
No Rights history available








